Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 10.89
(0.0%)
USD 10.89
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 178.43 Billion JPY | 6.53% |
| 2023 | 167.49 Billion JPY | 30.96% |
| 2022 | 128.53 Billion JPY | 5.8% |
| 2021 | 114.54 Billion JPY | 23.31% |
| 2020 | 91.92 Billion JPY | 24.82% |
| 2019 | 74.2 Billion JPY | 3.75% |
| 2018 | 67.38 Billion JPY | -11.44% |
| 2017 | 83.92 Billion JPY | 106.05% |
| 2016 | 36.88 Billion JPY | 63.85% |
| 2015 | 21.78 Billion JPY | -29.36% |
| 2014 | 31.66 Billion JPY | -5.98% |
| 2013 | 37.77 Billion JPY | -15.21% |
| 2012 | 43.01 Billion JPY | 7.06% |
| 2011 | 39.95 Billion JPY | -11.22% |
| 2010 | 46.15 Billion JPY | -8.11% |
| 2009 | 49.75 Billion JPY | -14.93% |
| 2008 | 62.89 Billion JPY | -2.73% |
| 2007 | 65.11 Billion JPY | -4.99% |
| 2006 | 63.77 Billion JPY | -4.58% |
| 2005 | 70.02 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 23.16 Billion JPY | -60.76% |
| 2024 Q1 | 47.14 Billion JPY | 43.58% |
| 2024 Q3 | 53.44 Billion JPY | -13.79% |
| 2024 FY | - JPY | 12.23% |
| 2024 Q2 | 61.49 Billion JPY | 31.31% |
| 2023 Q4 | 23.94 Billion JPY | -49.95% |
| 2023 Q2 | 46.5 Billion JPY | 6.6% |
| 2023 Q1 | 43.62 Billion JPY | 68.86% |
| 2023 FY | - JPY | 30.96% |
| 2023 Q3 | 47.82 Billion JPY | 2.85% |
| 2022 Q3 | 29.5 Billion JPY | -10.26% |
| 2022 Q4 | 25.83 Billion JPY | -12.45% |
| 2022 FY | - JPY | 5.8% |
| 2022 Q1 | 35.39 Billion JPY | 74.85% |
| 2022 Q2 | 32.88 Billion JPY | -7.11% |
| 2021 Q2 | 29.41 Billion JPY | -8.52% |
| 2021 Q1 | 32.15 Billion JPY | 110.45% |
| 2021 FY | - JPY | 23.31% |
| 2021 Q4 | 20.24 Billion JPY | -40.18% |
| 2021 Q3 | 33.83 Billion JPY | 15.03% |
| 2020 Q3 | 29.25 Billion JPY | 15.22% |
| 2020 FY | - JPY | 24.82% |
| 2020 Q4 | 15.28 Billion JPY | -47.76% |
| 2020 Q2 | 25.38 Billion JPY | 2.23% |
| 2020 Q1 | 24.83 Billion JPY | 94.57% |
| 2019 Q2 | 19.73 Billion JPY | -10.78% |
| 2019 Q3 | 21.06 Billion JPY | 6.76% |
| 2019 FY | - JPY | 3.75% |
| 2019 Q4 | 12.76 Billion JPY | -39.42% |
| 2019 Q1 | 22.11 Billion JPY | 98.72% |
| 2018 Q4 | 11.13 Billion JPY | -59.72% |
| 2018 Q3 | 27.63 Billion JPY | 85.8% |
| 2018 Q2 | 14.87 Billion JPY | -17.48% |
| 2018 Q1 | 18.02 Billion JPY | -12.95% |
| 2018 FY | - JPY | -11.44% |
| 2017 Q4 | 20.7 Billion JPY | -17.91% |
| 2017 FY | - JPY | 106.05% |
| 2017 Q2 | 14.9 Billion JPY | -27.15% |
| 2017 Q1 | 20.46 Billion JPY | 107.32% |
| 2017 Q3 | 25.22 Billion JPY | 69.17% |
| 2016 Q4 | 9.87 Billion JPY | 3.34% |
| 2016 Q1 | 15.05 Billion JPY | 10652.14% |
| 2016 Q2 | 4.35 Billion JPY | -71.06% |
| 2016 FY | - JPY | 63.85% |
| 2016 Q3 | 9.55 Billion JPY | 119.23% |
| 2015 Q2 | 1.71 Billion JPY | -69.21% |
| 2015 FY | - JPY | -29.36% |
| 2015 Q4 | 140 Million JPY | -99.16% |
| 2015 Q3 | 16.64 Billion JPY | 872.08% |
| 2015 Q1 | 5.56 Billion JPY | 13.52% |
| 2014 FY | - JPY | -5.98% |
| 2014 Q2 | 6.47 Billion JPY | -31.41% |
| 2014 Q3 | 13.92 Billion JPY | 114.97% |
| 2014 Q4 | 4.89 Billion JPY | -64.83% |
| 2014 Q1 | 9.44 Billion JPY | 250.07% |
| 2013 Q3 | -4.13 Billion JPY | -152.62% |
| 2013 FY | - JPY | -15.21% |
| 2013 Q1 | 27.58 Billion JPY | 234.76% |
| 2013 Q4 | 2.69 Billion JPY | 165.3% |
| 2013 Q2 | 7.85 Billion JPY | -71.54% |
| 2012 Q4 | -20.47 Billion JPY | -177.43% |
| 2012 Q3 | 26.43 Billion JPY | 216.66% |
| 2012 Q2 | 8.34 Billion JPY | -71.35% |
| 2012 Q1 | 29.14 Billion JPY | 281.08% |
| 2012 FY | - JPY | 7.06% |
| 2011 Q1 | 28.81 Billion JPY | 242.1% |
| 2011 Q2 | 10.5 Billion JPY | -63.54% |
| 2011 Q4 | -16.09 Billion JPY | -150.15% |
| 2011 FY | - JPY | -11.22% |
| 2011 Q3 | 32.09 Billion JPY | 205.46% |
| 2010 Q1 | 32.92 Billion JPY | 243.12% |
| 2010 FY | - JPY | -8.11% |
| 2010 Q2 | 15.74 Billion JPY | -52.2% |
| 2010 Q3 | 24.38 Billion JPY | 54.92% |
| 2010 Q4 | -20.28 Billion JPY | -183.16% |
| 2009 FY | - JPY | -14.93% |
| 2009 Q2 | 16.87 Billion JPY | 0.0% |
| 2009 Q4 | 9.59 Billion JPY | -40.84% |
| 2009 Q3 | 16.22 Billion JPY | -3.86% |
| 2008 FY | - JPY | -2.73% |
| 2007 FY | - JPY | -4.99% |
| 2006 FY | - JPY | -4.58% |
| 2005 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -1242.662% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | -818.963% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -15442.237% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 449501.839% |
| Novartis AG | 19.51 Billion USD | -814.215% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -61827.852% |